Galderma Pharmaceutical Expands in Quebec
Location Canada 2010
Galderma, which produces the skin care line Cetaphil, received more than $38 million from Investissement Quebec, the province's investment program, which targets product development projects by Quebec companies. The sum includes a non-refundable $3.8 million financial contribution that will help Galderma modernize and expand its drug manufacturing plant in Bai-d'Urfe.
"The government's support was a decisive factor in Galderma's decision to locate its center of excellence in Quebec," says Michel Sauvageau, manager of the Bai-d'Urfe plant. "In response to the progress of emerging countries in biopharmaceuticals, this investment in our manufacturing facility will increase its capacity and make it truly state-of-the-art."
The funds will also allow Galderma to consolidate 240 positions and create 30 new, specialized jobs.
Project Announcements
Belgium-Based Umicore Plans Ontario, Canada, Battery Materials Facility
07/20/2022
Odd Burger Corporation Plans London, Ontario, Manufacturing Complex
07/07/2022
indieDwell Plans Brawley, California, Manufacturing Plant
06/20/2022
Super-Pufft Snacks Plans Airdrie, Alberta, Manufacturing Facility
05/19/2022
Moderna Plans Quebec, Canada, Manufacturing-Operations Campus
05/13/2022
AMD Medicom Plans London, Ontario, Nitrile Glove Subsidiary
05/01/2022
Most Read
-
In Focus: “Golden Age” of Spec Development
Q3 2022
-
The 2021 Top States for Doing Business Reflect Their Locational Advantages
Q3 2021
-
Area Development’s 17th Annual Shovel Awards Recognize State and Local Economic Development Efforts — First Two Platinum Shovels Awarded
Q2 2022
-
In Focus: Demand for Industrial Land Surges
Q2 2022
-
Explosive Growth of Life Sciences Sector Comes with Challenges
Q3 2022
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
The Evolution of the Megasite
Q2 2022